Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension

NCT06785454 is registered in ClinicalTrials.gov with Mineralys Therapeutics Inc. as lead sponsor.

NCT NCT06785454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06785454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension
Lead sponsor
Mineralys Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2025
Completion date
December 29, 2025
Enrollment
48 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, obstructive sleep apnea